AngioDynamics reports results that beat analysts’ expectations, with outlets citing a modest earnings-per-share beat and revenue coming in above forecast. One source states the company’s earnings top estimates by $0.07, while another highlights that both top-line (revenue) and bottom-line (profit) figures exceed expectations.
In addition, the coverage notes that the company reaffirms its forward guidance. Seeking Alpha specifically references a reaffirmation of its FY26 outlook, indicating management continues to expect performance consistent with previously communicated targets. A separate Seeking Alpha item previews the company’s upcoming Q1 2027 earnings, framing expectations for the next reporting period, but does not indicate a change to the current quarter results described in the other articles.
Across outlets, the common emphasis is on the direction of the reported figures versus estimates and the status of the company’s outlook, while details on the upcoming quarter are treated as forward-looking context rather than part of the reported results.
